Comparative Activity of Carbapenem Antibiotics Against Gram-Negative Carbapenemase Producers of Different Groups

The rapid spread of gram-negative bacteria resistance to carbapenems due to the production of carbapenemases requires new treatment options. The activity of carbapenem antibiotic biapenem, recently registered in Russia, against producers of various carbapenemases was studied in comparison with other antibiotics of this group. Among NDM-type carbapenemase producers, 77.8% demonstrated clinical susceptibility to biapenem; 50.3% and 21.1% of isolates were susceptible to meropenem and imipenem, respectively. Among the producers of OXA-48-type carbapenemases, 82,6%, 60,9%, and 65,2% of isolates demonstrated susceptibility to biapenem, imipenem, and meropenem, respectively.Producers of KPC-type carbapenemases were 100% resistant to all carbapenems. The introduction of biapenem will significantly expand the possibilities of treating severe infections caused by carbapenemase producers.

1. Zhanel G.G., Wiebe R., Dilay L., Thomson K., Rubinstein E., Hoban D.J., Noreddin A.M., Karlowsky J.A. Comparative review of the carbapenems. Drugs. 2007; 67: 1027–1052. doi: 10.2165/00003495-200767070-00006.

2. Patel G., Bonomo R. «Stormy waters ahead»: global emergence of carbapenemases. Front Microbiol. 2013; 4: 48 doi: 10.3389/fmicb.2013.00048.

3. Walsh T.R., Toleman M.A., Poirel L., Nordmann P. Metallo-β-Lactamases: the quiet before the storm? Clin Microbiol Rev. 2005; 18: 306–325. doi:10.1128/CMR.18.2.306-325.2005.

4. Ambler R.P. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980; 289: 321–331. doi: 10.1098/rstb.1980.0049.

5. Lazareva I. V., Ageevets V.A., Ershova T.A., Zueva L.P., Goncharov A.E., Dar'ina M.G., Svetlichnaya Jyu.S.Jyu Gostev V.V., Sidorenko S.V. Rasprostranenie i antibakterial'naya rezistentnost' gramotritsatel'nykh bakterij, produtsentov karbapenemaz, v Sankt-Peterburge i nekotorykh drugikh regionakh Rossijskoj Federatsii. Antibiotiki i Khimioter. 2016; 61 (11–12): 28–38. (in Russian)

6. Livermore D.M., Mushtaq S., Morinaka A., Ida T., Maebashi K., Hope R. Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes. J Antimicrob Chemother. 2013; 68 (1): 153–158. doi: 10.1093/jac/dks350.

7. Livermore D.M., Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother. 2013; 68 (8): 1825–1831. doi: 10.1093/jac/dkt118.

8. Takata T., Aizawa K., Shimizu A., Sakakibara S., Watabe H., Totsuka K. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J Infect Chemother. 2004; 10 (2): 76–85. doi: 10.1007/s10156-003-0292-0.

9. Hoban D.J., Jones R.N., Yamane N., Frei R., Trilla A., Pignatari A.C. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis. 1993; 17 (4): 299–305. doi: 10.1016/0732-8893(93)90039-a.

10. Zhanel G.G., Lawson C.D., Adam H., Schweizer F., Zelenitsky S., Lagace-Wiens P.R. et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013; 73 (2): 159–177. doi: 10.1007/s40265-013-0013-7.

11. Smith J.R., Rybak J.M., Claeys K.C. Imipenem-cilastatin-relebactam: a novel beta-lactam-beta-lactamase inhibitor combination for the treatment of multidrug-resistant gram-negative infections. Pharmacotherapy. 2020; 40 (4): 343–356. doi: 10.1002/phar.2378.

12. Patel T.S., Pogue J.M., Mills J.P., Kaye K.S. Meropenem–vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. Future microbiology. 2018; 13 (9): 971–983. doi: 10.2217/fmb-2018-0054.

13. Lasko M.J., Nicolau D.P. Carbapenem-resistant enterobacterales: considerations for treatment in the era of new antimicrobials and evolving enzymology. Curr Infect Dis Rep. 2020; 22 (3): 6. doi: 10.1007/s11908-020-0716-3.

14. Sader H.S., Carvalhaes C.G., Arends S.J.R., Castanheira M., Mendes R.E. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother. 2021; 76 (3): 659–666. doi: 10.1093/jac/dkaa504.

15. Shaw E., Rombauts A., Tubau F., Padulles A., Camara J., Lozano T. et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018; 73 (4): 1104–1106. doi: 10.1093/jac/dkx496.

16. Choi J.J., McCarthy M.W. Cefiderocol: a novel siderophore cephalosporin. Expert opinion on investigational drugs. 2018; 27 (2): 193–197. doi: 10.1080/13543784.2018.1426745.

17. Zhanel G.G., Golden A.R., Zelenitsky S., Wiebe K., Lawrence C.K., Adam H.J. et al. Cefiderocol: A siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019; 79 (3): 271–289. doi: 10.1007/s40265-019-1055-2.

18. Bassetti M., Echols R., Matsunaga Y., Ariyasu M., D o i Y., Ferrer R. et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infectious Diseases. 2021; 21 (2): 226–240. doi: 10.1016/S1473-3099(20)30796-9.